medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Number 2

<< Back Next >>

Rev Invest Clin 2018; 70 (2)

Phenotypic Variability in a Mexican Mestizo Family with Retinal Vasculopathy with Cerebral Leukodystrophy and TREX1 Mutation p.V235Gfs*6

Monroy-Jaramillo N, Cerón A, León E, Rivas V, Ochoa-Morales A, Arteaga-Alcaraz MG, Nocedal-Rustrian FC, Gallegos C, Alonso-Vilatela ME, Corona T, Flores J

Language: English
References: 21
Page: 68-75
PDF size: 151.78 Kb.


ABSTRACT

Background: Retinal vasculopathy with cerebral leukodystrophy (RVCL) is an adult-onset, autosomal dominant disease involving microvessels of the brain and eye resulting in central nervous system degeneration with visual disturbances, stroke, motor impairment, and cognitive decline. Frameshift mutations at the C-terminus of TREX1 gene are the molecular cause of this disorder. Objectives: The objective of this study is to present the different clinical manifestations of RVCL in three-related patients and to investigate the presence of TREX1 mutation in the extended genealogy. Methods: Multidisciplinary testing was performed in three related patients. Based on their family history, the study was extended to 34 relatives from the same small community. Neurological evaluation, sequencing of TREX1, and presymptomatic diagnosis were offered to all participants. Results: The patients exhibited the heterozygous TREX1 mutation p.V235Gfs*6, but with phenotypic variability. In addition, 15 relatives were identified as pre-manifest mutation carriers. The remaining participants did not carry the mutation. Conclusions: This is the first report of a large Mexican genealogy with RVCL, where the same TREX1 mutation causes a variation in organ involvement and clinical progression. The early identification and follow-up of individuals at risk may help provide insights into the basis for this variability in presentation.


REFERENCES

  1. Richards A, van den Maagdenberg AM, Jen JC, et al. C-terminal truncations in human 3’-5’ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39:1068-70.

  2. Soong BW, Liao YC, Tu PH, et al. A homozygous NOTCH3 mutation p.R544C and a heterozygous TREX1 variant p.C99MfsX3 in a family with hereditary small vessel disease of the brain. J Chin Med Assoc. 2013;76:319-24.

  3. Di Francesco JC, Novara F, Zuffardi O, et al. TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy. Neurol Sci. 2015;36: 323-30.

  4. Kavanagh D, Spitzer D, Kothari PH, et al. New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle. 2008;7:1718-25.

  5. Federico A, Di Donato I, Bianchi S, et al. Hereditary cerebral small vessel diseases: a review. J Neurol Sci. 2012;322:25-30.

  6. Lindahl T, Barnes DE, Yang YG, Robins P. Biochemical properties of mammalian TREX1 and its association with DNA replication and inherited inflammatory disease. Biochem Soc Trans. 2009; 37:535-8.

  7. Orebaugh CD, Fye JM, Harvey S, et al. The TREX1 C-terminal region controls cellular localization through ubiquitination. J Biol Chem. 2013;288:28881-92.

  8. Alonso ME, Yescas P, Rasmussen A, et al. Homozygosity in Huntington’s disease: new ethical dilemma caused by molecular diagnosis. Clin Genet. 2002;61:437-42.

  9. Skirton H, Goldsmith L, Jackson L, et al. Quality in genetic counselling for presymptomatic testing—clinical guidelines for practice across the range of genetic conditions. Eur J Hum Genet. 2013;21:256-60.

  10. Stam AH, Kothari PH, Shaikh A, et al. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain. 2016;139:2909-22.

  11. Hardy TA, Young S, Sy JS, et al. Tumefactive lesions in retinal vasculopathy with cerebral leucoencephalopathy and systemic manifestations (RVCL-S): a role for neuroinflammation? J Neurol Neurosurg Psychiatry. 2017 Aug 9 [Epub ahead of print].

  12. Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy. A new hereditary syndrome. Ophthalmology. 1988;95:649-59.

  13. Mateen FJ, Krecke K, Younge BR, et al. Evolution of a tumor-like lesion in cerebroretinal vasculopathy and TREX1 mutation. Neurology. 2010;75:1211-3.

  14. Vodopivec I, Oakley DH, Perugino CA, et al. A 44-year-old man with eye, kidney, and brain dysfunction. Ann Neurol. 2016;79: 507-19.

  15. Schuh E, Ertl-Wagner B, Lohse P, et al. Multiple sclerosis-like lesions and Type I interferon signature in a patient with RVCL. Neurol Neuroimmunol Neuroinflamm. 2015;2:e55

  16. Stüve O, Oksenberg J. Multiple Sclerosis Overview. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. Gene Reviews®. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20301492 [Last updated on 2010 May 11]; [Last accessed on 2018 Jan 19].

  17. Wallner-Blazek M, Rovira A, Fillipp M, et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol. 2013;260:2016-22.

  18. Ben-Nun A, Kaushansky N, Kawakami N, et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J Autoimmun. 2014;54:33-50.

  19. Poser S, Lüer W, Bruhn H, et al. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand. 1992;86:579-85.

  20. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody- associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23-32.

  21. Kisla Ekinci RM, Balci S, Bisgin A, Altintas DU, Yilmaz M. A homozygote TREX1 mutation in two siblings with different phenotypes: chilblains and cerebral vasculitis. Eur J Med Genet. 2017; 60:690-4.




2020     |     www.medigraphic.com